Christopher C. Dvorak
Expertise in
15
conditions

Dr. Christopher C. Dvorak

Pediatric Hematology Oncology | Pediatrics | Hematology
Ucsf Pediatrics Associates
1975 4th St, 
San Francisco, CA 
Clinical Trials:Currently Recruiting for 3 Trials
23 Years of Experience
Expertise in
15
conditions
Ucsf Pediatrics Associates
1975 4th St, 
San Francisco, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Christopher Dvorak is a Pediatric Hematologist Oncology specialist and a Pediatrics provider in San Francisco, California. Dr. Dvorak has been practicing medicine for over 23 years is highly rated in 15 conditions, according to our data. His top areas of expertise are Severe Combined Immunodeficiency (SCID), Juvenile Myelomonocytic Leukemia (JMML), Hepatic Venoocclusive Disease with Immunodeficiency, Bone Marrow Transplant, and Splenectomy.

His clinical research consists of co-authoring 212 peer reviewed articles and participating in 18 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pediatric Hematology Oncology
Pediatrics
Hematology
Licenses
Pediatric Hematology-Oncology in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

UCSF PEDIATRICS ASSOCIATES
1975 4th St, San Francisco, CA 94143
Other Locations
UCSF PEDIATRICS ASSOCIATES
505 Parnassus Ave, San Francisco, CA 94143

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

A Feasibility Study of Using the CiniMacs® Device for Alpha/Best T-Cell Depletion in Stem Cell Transplant Recipients
A Feasibility Study of Using the CiniMacs® Device for Alpha/Best T-Cell Depletion in Stem Cell Transplant Recipients
Enrollment Status: Recruiting
Publish Date: March 30, 2025
Intervention Type: Device
Study Phase: Not Applicable
A Randomized Trial of Low Versus Moderate Exposure Busulfan for Infants with Severe Combined Immunodeficiency (SCID) Receiving TCRαβ+/CD19+ Depleted Transplantation: a Phase II Study by the Primary Immune Deficiency Treatment Consortium (PIDTC) and Pediatric Blood and Marrow Transplant Consortium (PBMTC)
A Randomized Trial of Low Versus Moderate Exposure Busulfan for Infants with Severe Combined Immunodeficiency (SCID) Receiving TCRαβ+/CD19+ Depleted Transplantation: a Phase II Study by the Primary Immune Deficiency Treatment Consortium (PIDTC) and Pediatric Blood and Marrow Transplant Consortium (PBMTC)
Enrollment Status: Recruiting
Publish Date: March 25, 2025
Intervention Type: Drug, Device
Study Drug: Busulfan
Study Phase: Phase 2
Longitudinal Evaluation of Recipients of Hematopoietic Stem Cell Transplantation (HSCT)
Longitudinal Evaluation of Recipients of Hematopoietic Stem Cell Transplantation (HSCT)
Enrollment Status: Recruiting
Publish Date: December 18, 2024
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of JSP191 for Hematopoietic Cell Transplantation Conditioning to Achieve Engraftment and Immune Reconstitution in Subjects with SCID
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of JSP191 for Hematopoietic Cell Transplantation Conditioning to Achieve Engraftment and Immune Reconstitution in Subjects with SCID
Enrollment Status: Active_not_recruiting
Publish Date: March 26, 2025
Intervention Type: Biological
Study Drug: Humanized anti-CD117 Monoclonal Antibody
Study Phase: Phase 1/Phase 2
A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT)
A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT)
Enrollment Status: Completed
Publish Date: October 16, 2024
Intervention Type: Drug, Other
Study Phase: Phase 3
The Effectiveness of Lactobacillus Plantarum (LBP, IND# 17339) in Preventing Acute Graft-Versus-Host Disease (GvHD) in Children Undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT)
The Effectiveness of Lactobacillus Plantarum (LBP, IND# 17339) in Preventing Acute Graft-Versus-Host Disease (GvHD) in Children Undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT)
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2024
Intervention Type: Procedure, Other, Biological
Study Drugs: Lactobacillus Plantarum Strain 299, Lactobacillus Plantarum Strain 299v
Study Phase: Phase 3
Pilot Study -- Oral Microbiome and Dental Plaque Control With Livionex(R) in Children Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
Pilot Study -- Oral Microbiome and Dental Plaque Control With Livionex(R) in Children Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
Enrollment Status: Completed
Publish Date: September 23, 2024
Intervention Type: Drug, Device
Study Phase: Phase 1
Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation (ACES) PBMTC SUP1701
Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation (ACES) PBMTC SUP1701
Enrollment Status: Active_not_recruiting
Publish Date: December 15, 2023
Intervention Type: Biological
Study Drug: Virus Specific T-cell infusion
Study Phase: Phase 1/Phase 2
Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
Enrollment Status: Unknown
Publish Date: February 08, 2023
An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
Enrollment Status: No_longer_available
Publish Date: March 14, 2022
Intervention Type: Drug
A Pilot Trial of Using Pre-Transplant Risk Stratification and Prophylactic Defibrotide to Prevent Serious Thrombotic Microangiopathy in High-Risk Hematopoietic Stem Cell Transplant Patients
A Pilot Trial of Using Pre-Transplant Risk Stratification and Prophylactic Defibrotide to Prevent Serious Thrombotic Microangiopathy in High-Risk Hematopoietic Stem Cell Transplant Patients
Enrollment Status: Completed
Publish Date: September 16, 2021
Intervention Type: Drug
Study Phase: Phase 2
Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995
Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995
Enrollment Status: Unknown
Publish Date: September 02, 2021
Impact of Cleansing With Chlorhexidine Gluconate (CHG) on Reducing Central Line Associated Bloodstream Infection (CLABSI) and Acquisition of Multi-drug Resistant Organisms (MDRO) in Children With Cancer or Those Receiving Allogeneic Hematopoietic Cell Transplantation (HCT)
Impact of Cleansing With Chlorhexidine Gluconate (CHG) on Reducing Central Line Associated Bloodstream Infection (CLABSI) and Acquisition of Multi-drug Resistant Organisms (MDRO) in Children With Cancer or Those Receiving Allogeneic Hematopoietic Cell Transplantation (HCT)
Enrollment Status: Completed
Publish Date: June 22, 2021
Intervention Type: Procedure, Other
Study Phase: Phase 3
A Randomized Trial of Levofloxacin to Prevent Bacteremia in Children Being Treated for Acute Leukemia (AL) or Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
A Randomized Trial of Levofloxacin to Prevent Bacteremia in Children Being Treated for Acute Leukemia (AL) or Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
Enrollment Status: Completed
Publish Date: December 07, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Retrospective and Cross-Sectional Analysis of Patients Treated for SCID Since January 1,1968 (RDCRN PIDTC-6902)
A Retrospective and Cross-Sectional Analysis of Patients Treated for SCID Since January 1,1968 (RDCRN PIDTC-6902)
Enrollment Status: Unknown
Publish Date: November 12, 2020
A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children With SCID Disorders (RDCRN PIDTC-6901)
A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children With SCID Disorders (RDCRN PIDTC-6901)
Enrollment Status: Enrolling_by_invitation
Publish Date: November 10, 2020
View 13 Less Clinical Trials

212 Total Publications

Integrating Pulmonary and Systemic Transcriptomic Profiles to Characterize Lung Injury after Pediatric Hematopoietic Stem Cell Transplant.
Integrating Pulmonary and Systemic Transcriptomic Profiles to Characterize Lung Injury after Pediatric Hematopoietic Stem Cell Transplant.
Journal: medRxiv : the preprint server for health sciences
Published: April 16, 2025
Similar Doctors
Expertise in
15
conditions
Dr. Ashutosh P. Lal
Pediatric Hematology Oncology | Pediatrics | Hematology
Expertise in
15
conditions
Dr. Ashutosh P. Lal
Pediatric Hematology Oncology | Pediatrics | Hematology

University Of California San Francisco

505 Parnassus Ave, 
San Francisco, CA 
 (3.7 mi)
415-476-1000
Languages Spoken:
English, Hindi, Punjabi, Urdu
See accepted insurances
Offers Telehealth

Ashutosh Lal is a Pediatric Hematologist Oncology specialist and a Pediatrics provider in San Francisco, California. Dr. Lal is highly rated in 15 conditions, according to our data. His top areas of expertise are Thalassemia, Beta Thalassemia, Congenital Hemolytic Anemia, Hemoglobinopathy, and Splenectomy.

Expertise in
10
conditions
Dr. Mark C. Walters
Pediatric Hematology Oncology | Hematology | Oncology
Expertise in
10
conditions
Dr. Mark C. Walters
Pediatric Hematology Oncology | Hematology | Oncology
747 52nd Street, 
Oakland, CA 
 (8.4 mi)
510-428-3374
Languages Spoken:
English
See accepted insurances

Mark Walters is a Pediatric Hematologist Oncology specialist and a Hematologist in Oakland, California. Dr. Walters is highly rated in 10 conditions, according to our data. His top areas of expertise are Hemoglobinopathy, Congenital Hemolytic Anemia, Sickle Cell Disease, Hemolytic Anemia, and Bone Marrow Transplant.

Hope S. Rugo
Expertise in
18
conditions
Dr. Hope S. Rugo
Hematology | Oncology
Expertise in
18
conditions
Dr. Hope S. Rugo
Hematology | Oncology

Ucsf Medical Group Business Services

400 Parnassus Ave, 
San Francisco, CA 
 (3.7 mi)
415-476-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Hope Rugo is a Hematologist and an Oncologist in San Francisco, California. Dr. Rugo is highly rated in 18 conditions, according to our data. Her top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, Agranulocytosis, Bone Marrow Aspiration, and Hormone Replacement Therapy (HRT).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dvorak's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 32 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile